Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › NSCLC

NSCLC

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for NSCLC

25 trials tracked for NSCLC: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 104 citations.

25Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 17 Phase 1 3 Other / NA 2
  1. Phase 3 Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) Completed · 104 cited
  2. Phase 3 Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC Completed · 36 cited
  3. Phase 3 Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC) Completed
  4. Phase 2 Afatinib in NSCLC With HER2 Mutation Completed
  5. Phase 2 Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Completed
  6. Phase 2 A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) Completed
Show 19 more trials
  1. Phase 2 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer Completed
  2. Phase 2 Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer Completed
  3. Phase 2 A Rollover Protocol of Dacomitinib For Patients In Japan Completed
  4. Phase 2 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) Completed
  5. Phase 2 Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC Completed
  6. Phase 2 Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) Completed
  7. Phase 2 Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies Completed
  8. Phase 2 Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy Completed
  9. Phase 2 Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC Completed
  10. Phase 2 Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC Completed
  11. Phase 2 TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas Completed
  12. Phase 2 Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) Completed
  13. Phase 2 Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies Completed
  14. Phase 2 Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer Completed
  15. Phase 1 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors Completed
  16. Phase 1 A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors Completed
  17. Phase 1 A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors Completed
  18. N/A Descriptive Observational Study ALK-2016-CPHG Completed
  19. N/A EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer Completed

Showing the 25 most-cited and recently-updated of 25 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

NSCLC: what the trials found

Durvalumab has demonstrated a favorable safety profile in clinical trials, with zero participants experiencing Grade 3 or Grade 4 clinical laboratory toxicities in specific cohorts 13. Additionally, Durvalumab was evaluated in other established studies 10.

Erlotinib showed a 3-year survival rate of 37% to 41% in patients 3. Other established interventions include immune checkpoint inhibitors combined with docetaxel 1 and bevacizumab in combination with paclitaxel/carboplatin 2.

Recent results — preliminary, needs further review

  • Osimertinib showed progression-free system (PFS) rates at 18 months of 51.1%, 67.2%, and 53.5% 4.
  • E-602 was evaluated in a Phase 2 trial 5.

For the clinician treating this condition

  • Durvalumab is associated with low rates of high-grade clinical laboratory toxicities 13.
  • Erlotinib has established survival data for long-term outcomes 3.
  • Osimertinib shows varying progression-free rates at the 18-month mark 4.

AI synthesis of 7 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Alectinib improves progression-free survival over crizotinib in ALK-positive NSCLC (HR 0.41)
Oncology Phase III
Alectinib improves progression-free survival over crizotinib in ALK-positive NSCLC (HR 0.41) Alectinib Shows Better Progression-Free Survival Than Crizotinib for NSCLC
This pooled analysis of Phase III trials involving 500 patients with ALK-positive NSCLC found that alectinib significantly improved progress…
Alectinib showed better progression-free survival than crizotinib in a study of 500 patients with ALK-positive lung cancer.
Jul 27, 2026
Robotic-assisted thoracoscopic segmentectomy increases lymph node stations examined and reduces hospital stay duration
Oncology Meta-analysis
Robotic-assisted thoracoscopic segmentectomy increases lymph node stations examined and reduces hospital stay duration Robotic surgery may help lung cancer patients stay in hospital less
This meta-analysis of 19,805 patients with early-stage NSCLC compares robotic-assisted thoracoscopic segmentectomy (RATS) to video-assisted …
A large review suggests robotic-assisted surgery for early-stage lung cancer can lead to more lymph node checks and shorter hospital stays.
Jul 21, 2026
CT-based immune radiomic signature shows association with prognosis in non-small cell lung cancer
Oncology Cohort
CT-based immune radiomic signature shows association with prognosis in non-small cell lung cancer CT scans may help predict lung cancer treatment response
This cohort study utilized a CT-based immune radiomic signature, known as CT-RadScore, across multiple patient cohorts including TCIA, TCGA,…
A new way to analyze CT scans could help doctors predict how lung cancer patients respond to immunotherapy and other drugs.
Frontiers Apr 30, 2026
Phase 2 trial finds no significant PFS benefit adding SABR to nivolumab in advanced NSCLC
Pulmonology & Critical Care RCT
Phase 2 trial finds no significant PFS benefit adding SABR to nivolumab in advanced NSCLC Does adding targeted radiation to immunotherapy help advanced lung cancer?
A phase 2 randomized trial in 50 adults with metastatic NSCLC found no significant difference in 6-month progression-free survival (49% vs 4…
Adding high-dose radiation to immunotherapy did not improve outcomes or reduce side effects for advanced lung cancer patients who had alread…
Apr 2, 2026